Last mentioned: Mar 20, 2026
Current Assessment
Industry reports highlight the persistent gap between regulatory goals and technological capabilities.
NAMs Investment Surge
Significant venture capital and federal funding shift toward New Approach Methodologies (NAMs).
FDA Modernization Act 2.0
President Biden signs legislation ending the requirement for animal testing for new drug protocols.
EU Cosmetics Ban
The European Union implements a full ban on the sale of animal-tested cosmetics.
Global regulators are accelerating the transition toward non-animal testing methods in drug development, yet a significant innovation gap remains. While the FDA and EU have eased mandates, current AI and organ-on-a-chip technologies cannot yet fully replicate the systemic complexity of living organisms.